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ABSTRACT 
Objectives: In non-alcoholic fatty liver disease (NAFLD), hepatic steatosis is intricately 
linked with a number of metabolic alterations. We studied substrate utilization in NAFLD 
during basal, insulin-stimulated and exercise conditions, and correlated these outcomes with 
disease severity.  
Methods: 20 patients with NAFLD (BMI 34.16.7 kg/m2) and 15 healthy controls (23.42.7 
kg/m2) were assessed. Respiratory quotient (RQ), whole-body fat (Fatox) and carbohydrate 
(CHOox) oxidation rates were determined by indirect-calorimetry in three conditions: basal 
(resting and fasted), insulin-stimulated (hyperinsulinemic-euglycemic clamp) and exercise 
(cycling at the intensity eliciting maximal Fatox). Severity of disease and steatosis was 
determined by liver histology; hepatic Fatox from plasma -hydroxybutyrate concentrations; 
aerobic fitness as 
VO2 peak ; visceral adipose tissue (VAT) by computed tomography.  
Results: Within the overweight/obese NAFLD cohort, basal RQ was positively correlated 
with steatosis (r=0.57, P=0.01) and was higher (indicating smaller contribution of Fatox to 
energy expenditure) in patients with NAFLD activity score 5 vs. <5 (P=.008). Both results 
were independent of VAT, %body fat and BMI. Compared to the lean control group, patients 
with NAFLD had lower basal whole-body Fatox (P=0.024) and lower basal hepatic Fatox (i.e 
-hydroxybutyrate, P=0.004). During exercise they achieved lower maximal Fatox (P=0.002) 
and lower 
VO2 peak  (P<0.001) than controls. Fatox during exercise was not associated with 
disease severity (P=0.79). 
Conclusions: Overweight/obese patients with NAFLD had reduced hepatic Fatox and reduced 
whole-body Fatox under basal and exercise conditions. There was an inverse relationship 
between ability to oxidize fat in basal conditions and histological features of NAFLD 
including severity of steatosis and NAFLD activity score.  
  
SIGNIFICANCE OF THIS STUDY  
What is already known about this subject? 
 NAFLD is the most prevalent liver disease in industrialized countries and is associated 
with a number of metabolic alterations.  
 In NAFLD, studies investigating whole-body and hepatic fat oxidation reported 
conflicting results. Further, it is not known whether the severity of NAFLD is 
associated with whole-body substrate oxidation rates. 
 Maximal fat oxidation achieved during exercise has not been studied in NAFLD.  
What are the new findings? 
 Whole-body fat oxidation at rest and during exercise is reduced in overweight/obese 
patients with NAFLD. 
 In overweight/obese patients with NAFLD, reduced whole-body fat oxidation in basal 
conditions is associated with degree of steatosis and histological severity of disease, 
independent of BMI, body fatness and visceral adipose tissue. 
 Basal hepatic fat oxidation is reduced in overweight/obese patients with NAFLD. 
How might it impact on clinical practice in the forseeable future? 
 Behavioural or pharmacological therapies that can promote whole-body and hepatic 
fat oxidation in basal and exercise conditions could be useful for the treatment of 
NAFLD. 
 Exercise training could be a suitable treatment option for NAFLD because, in addition 
to improving aerobic fitness and insulin sensitivity, it also promotes fat oxidation in 
basal and exercise conditions. 
  
INTRODUCTION 
The most prevalent liver disease in industrialized countries is non-alcoholic fatty liver disease 
(NAFLD).[1] NAFLD encompasses a spectrum of histological features ranging from simple 
steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Development and 
progression of NAFLD are intricately linked with a number of factors including genetic 
predisposition,[2, 3] physical inactivity, obesity and insulin resistance (IR).[4, 5] Hepatic 
steatosis appears to be a prerequisite for more severe liver injury and occurs when the rates of 
de novo hepatic fatty acid synthesis and of hepatic fatty acid uptake from plasma exceed the 
rate of hepatic fat oxidation and triglyceride (TG) export.[6] There is evidence that patients 
with NAFLD have increased free fatty acid delivery from the adipose tissue,[7] increased de 
novo hepatic fatty acid synthesis[8] and increased TG export.[9] On the other hand, it is less 
clear whether patients with NAFLD have altered whole-body and hepatic fat oxidation 
(Fatox).  
An ideal cadre to study whole-body substrate metabolism is to assess substrate oxidation rates 
under a number of physiological conditions including the basal state (resting and fasting 
conditions), after a meal or insulin stimulation and during exercise.[10] Studies investigating 
whole-body substrate oxidation of NAFLD patients in the basal state have reported 
conflicting results. Perseghin et al.[11] found lower rates of whole-body Fatox in obese 
adolescents with NAFLD compared to counterparts without fatty liver. In contrast, Bugianesi 
et al.[12] reported a tendency for higher rates of whole-body Fatox in 12 non-obese patients 
with NAFLD when compared with 6 body mass index (BMI)-matched controls. Similarly, 
Sanyal et al.[13] found higher Fatox in 6 obese NAFLD compared to 6 obese NASH, although 
both NAFLD and NASH groups did not differ from 6 lean controls. Krotonen et al.[14] found 
no significant difference between 29 moderately overweight individuals with NAFLD and 29 
leaner healthy control. In the latter group of studies[12, 13, 14] between-group differences in 
  
hepatic Fatox mirrored those for whole-body Fatox. In the insulin-stimulated state, results are 
more uniform with NAFLD patients showing a reduced insulin-mediated suppression of Fatox 
compared to controls.[11, 12, 14] To date, substrate oxidation during exercise has not been 
compared between patients with NAFLD and counterparts without fatty liver. It is important 
to better understand substrate metabolism during exercise because whole-body metabolic 
demands are increased and potential abnomalities not seen in the resting state may become 
apparent. Further, exercise training is increasingly recommended clinically as a component of 
lifesyle interventions.[15, 16] 
Differences in severity of liver disease in previous cohorts may have contributed to the 
contrasting results reported on basal substrate metabolism in NAFLD. However, the 
relationship between severity of disease (which can only be assessed by liver histology) and 
substrate oxidation under various metabolic conditions has not been investigated to date in 
adults with NAFLD. In obese adolescents with NAFLD, hepatic steatosis (measured by 
magnetic resonance spectroscopy) and impairment in basal whole-body Fatox were shown to 
be positively correlated, independent of BMI.[11] 
 
The objective of this study was to measure substrate utilization under basal, insulin-stimulated 
and exercise conditions in adult patients with NAFLD and to explore whether these outcome 
measures were correlated with degree of steatosis and severity of liver disease. 
METHODS 
Participants 
Twenty overweight/obese patients with NAFLD and 15 lean healthy controls participated in 
the study. Patients were recruited from outpatient hospital clinics and NAFLD was diagnosed 
clinically and on liver biopsy. Exclusion criteria included the presence of other causes of liver 
  
disease (serologically and on history), evidence of cirrhosis or decompensated liver disease, 
alcohol consumption >40 g/day in males or >20 g/day in females (assessed by detailed 
clinical history) and type 2 diabetes. Control participants were healthy non-obese adults with: 
normal liver enzymes (alanine transaminase <35 U/L; aspartate aminotransferase <35 U/L), 
no evidence of liver disease (serologically and on history), no hepatomegaly on clinical 
examination and no features of the metabolic syndrome.[17] Controls were non-smoking, not 
taking regular medications and had minimal alcohol intake. In individuals meeting these same 
criteria, the prevalence of steatosis has been shown to be 5%[18] or lower.[19] The study was 
approved by the Human Research Ethics Committees of the Princess Alexandra Hospital and 
the University of Queensland. Informed written consent was obtained from all participants. 
While we considered the benefit of an additional obese non-NAFLD control group, the 
prospective liver biopsy of control participants for the purpose of this study was deemed 
unethical by the ethics committee and therefore exclusion of NAFLD in an obese control was 
not possible for this study. Further, it could be argued that obese individuals without steatosis 
are metabolically atypical[20] and therefore not an appropriate control group. Instead, it has 
been proposed that healthier physically active individuals should be assigned as a control 
group.[21] Accordingly, this study compares measurements in NAFLD to a healthy reference 
and then further explores study aims regarding disease severity within the NAFLD group 
alone. 
General design 
Each participant undertook testing in the morning after a 10-12 hour overnight fast on two 
occasions within a 7-day period. The first testing session involved a hyperinsulinemic-
euglycemic clamp with indirect calorimetry measurements to assess substrate oxidation rates 
in two conditions: basal (in resting and fasted conditions) and insulin-stimulated (during the 
steady state of a hyperinsulinemic-euglycemic clamp). The second testing session involved 
  
indirect calorimetry measurement during a graded exercise test on a cycle ergometer to assess 
substrate oxidation rate and VO2max  (aerobic fitness).  
Histological analysis of liver biopsy 
Liver biopsy specimens were fixed in 10% neutral buffered formalin, embedded in paraffin, 
and were subsequently scored by an expert hepatopathologist (AC). The percentage of 
hepatocytes with steatosis was estimated. The severity of liver injury was assessed using the 
NAFLD activity score (NAS)[22] and the criteria described by Brunt.[23] A diagnosis of 
steatosis alone or NASH was made using conventional histologic criteria, independent of 
NAS.[24]  
Body composition 
Fat mass and fat-free mass (FFM) were measured by dual-energy X-ray absorptiometry (GE 
Lunar Prodigy enCore 2005, General Electric, Madison, WI). In the NAFLD group 
distribution of abdominal fat (visceral and subcutaneous) was determined by computed 
tomography (Philips Brilliance 16, Cleveland, OH) as previously described.[25]  
Hyperinsulinemic-euglycemic clamp 
Insulin sensitivity was evaluated by the hyperinsulinemic-euglycemic clamp technique,[26] 
with a protocol previously described.[12] Teflon catheters were placed into an antecubital 
vein for infusions, and into a dorsal hand vein (heated to 55C to achieve arterialization of 
venous blood) for sampling. After obtaining a basal blood sample, primed insulin infusion 
was initiated at a rate of 1 mUkg-1min-1 (Humulin R; Eli Lilly, Indianapolis, IN) and was 
maintained at a constant rate throughout the procedure (120 minutes). Plasma glucose 
concentration was monitored every 5 minutes using an automated glucose analyzer (YSI 2300 
Stat Plus, YSI Life Sciences, Yellow Springs, OH). Euglycemia was maintained infusing a 
25% glucose solution at a variable rate.[26] 
  
 The glucose infusion rate in the steady-state of the hyperinsulinemic-euglycemic clamp (M-
value) represented whole-body glucose disposal rate. Non-oxidative glucose disposal rate was 
calculated by subtracting the oxidative glucose disposal rate (CHOox during the insulin-
stimulated state determined by indirect calorimetry) from the M-value. The insulin sensitivity 
index (M/I), a measure of the quantity of glucose metabolized per unit of insulin 
concentration, was calculated by dividing M-value by the insulin concentation reached in the 
insulin-stimulated state.[26] An index of adipocyte IR (adipo-IR) was calculated as the 
product of the fasting plasma free fatty acids (FFA) and insulin concentration.[27]  
Biochemical analysis  
Blood samples were drawn at 10-minute intervals during the last 40 minutes of the 
hyperinsulinemic-euglycemic clamp. Glucose was analyzed using an automated glucose 
analyzer interassay coefficient of variation (CV) 2%. Insulin was assayed using an 
immunoenzymatic assay with chemiluminescence detection (Unicel DxI 800 Immunoassay 
System, Beckman Coulter, Brea, CA). Total cholesterol, high-density lipoprotein-cholesterol 
and TG were assayed by an enzymatic colorimetric assay with Roche Modular Chemistry 
Analyzer (South San Francisco, CA). Low-density lipoprotein-cholesterol and very low 
density lipoprotein were calculated using the Friedewald equation.[28] Serum FFA 
concentrations were measured with an in vitro enzymatic colorimetric method (Wako NEFA 
assay, Wako chemicals, Richmond, VA, CV 2.3%). Plasma β-hydroxybutyrate 
concentrations, an index of hepatic ketogenesis,[29] were measured enzymatically (Stanbio, 
Boerne, TX, CV 2.2%).  
Graded exercise test 
 Maximal aerobic power and substrate utilization were assessed with a graded exercise test on 
a cycle ergometer. Testing included a sub-maximal phase to assess energy expenditure, Fatox 
and CHOox at various intensities, and a maximal phase to determine peak oxygen 
  
consumption (
VO2 peak ). The starting workload for the submaximal phase was individualized at 
20% of the theoretical maximal mechanical work.[30] Workload was increased by 10% at 
each stage until the respiratory exchange ratio was above 1.0 during the last minute of the 
stage. Stages lasted 5 minutes and were separated by 2-minute rest intervals. The maximal 
phase started at a workload corresponding to two stages below the intensity reached at the end 
of the submaximal phase, and workload was incremented by 10% every minute until 
volitional exhaustion.  
Indirect calorimetry 
Indirect calorimetry measurements (TrueOne 2400 Metabolic Measurement System, Parvo 
Medics, UT) to determine oxygen consumption ( VO2 ) and carbon dioxide production (VCO2 ) 
were performed in three conditions: 1) basal, 2) insulin-stimulated and 3) exercise. Basal and 
insulin-stimulated measurements lasted 20 minutes with participants lying supine and 
breathing through a ventilated hood. Measurements during the graded exercise test were 
performed continuously, with participants wearing mouthpiece and nose clip.  
Whole-body respiratory quotient (RQ) was calculated as VCO2 / VO2 . Whole-body Fatox and 
CHOox were calculated using stoichiometric equations and appropriate energy equivalents, 
with the assumption that the urinary nitrogen excretion rate was negligible.[31] Average 
values of VO2  and VCO2  were calculated during the last 10 minutes of basal and insulin-
stimulated periods, and during the last minute of each submaximal exercise stage. 
Subsequently, Fatox values determined at each stage of the exercise test were graphically 
depicted as a function of exercise intensity. The stage at which the value of measured Fatox 
rate was maximal (maximal fat oxidation, MFO) was determined and the corresponding 
intensity identified (Fatmax).[32] Data measured at Fatmax were employed for comparison 
  
between groups. M-value, energy expenditure and substrate oxidation rates were corrected for 
FFM.  
Statistical analysis 
Data are expressed as the mean ± standard deviation for all variables. Student t-tests for 
independent samples were used to compare the mean values between groups categorised 
according to cohort (NAFLD vs. controls), disease severity (NAFLD with NAS<5 vs. 
NAFLD with NAS5), and BMI (NAFLD with BMI < or 33 kg/m2). Paired Student t-tests 
were used to compare energy expenditure and substrate oxidation rates in different conditions 
within groups. Analysis of covariance was used to adjust for FFM. Association between 
continuous variables was assessed using Spearman’s non-parametric rank correlation 
coefficient and multivariate analysis. Statistical analysis was performed with the software 
SPSS 17.0 for Windows (SPSS, Chicago, IL) and Graph Pad Prism version 5.0 for Mac 
(GraphPad Software, San Diego, CA). For all statistical analyses, the level of significance 
was set at P<0.05. 
RESULTS  
Participant characteristics  
Characteristics of study groups are presented in Table 1. Liver histology from patients with 
NAFLD showed macrovesicular steatosis ranging from 10 to 100%, with an average of 
7131%. Sixteen patients were diagnosed with NASH, while four with steatosis alone. 
Fourteen patients had a NAS5, while six patients had a NAS<5. Fibrosis was observed in 10 
patients (stage 1 in 3, stage 2 in 4, and stage 3 in 3).  
Age and gender were not significantly different between NAFLD and controls. BMI and 
percentage of body fat were higher in the NAFLD group in comparison with controls. Patients 
with NAFLD had higher fasting plasma TG, insulin and glucose, while fasting plasma FFA 
  
were not different between groups. In the NAFLD cohort, visceral adipose tissue area was 
194 ± 94 cm2, while  subcutaneous adipose tissue area was 384 ± 197 cm2. 
 
Table 1. Demographic, anthropometric, and laboratory characteristics of the study groups 
 Control  (n=15) NAFLD (n=20) P-value 
Age (years) 41  11 48  11 0.07 
Gender (M:F) 10:5 12:8 0.92 
BMI (kg/m2) 23.4  2.7 34.1  6.7 < 0.001 
Weight (kg) 71.2   12.4 101.2   26.9 < 0.001 
Fat mass (%) 25.0  6.3 38.5  8.0 < 0.001 
Fat-free mass (kg)  53.4  10.4 61.5  15.3 0.08 
Waist (cm) 82.0  7.5 112.7  18.0 < 0.001 
Triglycerides (mmol/L)  0.51 ± 0.24 1.9 ± 1.03 < 0.001 
HDL cholesterol (mmol/L)  1.37 ± 0.33 0.92 ± 0.28 < 0.001 
LDL cholesterol (mmol/L) 2.77 ± 0.89 3.22 ± 1.0 0.17 
VLDL cholesterol (mmol/L) 0.23 ± 0.11 0.86 ± 0.47 < 0.001 
-Hydroxybutyrate (mmol/L) 0.14  0.07 0.09   0.03 0.004 
Fasting free fatty acids (mmol/L) 0.63  0.18 0.58  0.18 0.43 
Fasting glucose (mmol/L) 5.0  0.4 5.5  0.4 0.002 
Fasting insulin (mU/L) 3.4  2.0 20.2  16.7 < 0.001 
Fasting C-peptide (nmol/L) 0.51  0.18 1.37   0.73 < 0.001 
Alanine aminotransferase (U/L) 19.9  6.5 65.7  42.2 < 0.001 
Aspartate aminotransferase (U/L) 21.8  7.1 42.0  22.2 0.002 
BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low 
density lipoprotein. 
 
Insulin resistance 
Patients with NAFLD were severely insulin resistant (Table 2), with lower M-value compared 
to lean controls (4.11.5 vs. 9.12.2 mgkgFFM-1min-1, P<0.001), and demonstrated 
  
impairment in both the oxidative (3.00.7 vs. 3.60.7 mgkgFFM-1min-1, P=0.04) and the 
non-oxidative glucose disposal pathways (1.81.3 vs. 5.12.4 mgkgFFM-1min-1, P<0.001).  
The insulin sensitivity index M/I was also significanly lower in NAFLD (5.93.6 vs. 17.15.1 
(mgkgFFM-1min-1)(mUL-1)-1, P<0.001), showing that the differences between groups were 
maintained after adjusting for the insulin levels reached (80.626.9 in NAFLD vs. 51.27.9 
mU/L in control, P<0.001). Adipo-IR was more severe in NAFLD patients compared to 
controls (11.18.6 vs. 2.21.3 mmolmUL-2, P<0.001) and in NAFLD patients with fibrosis 
compared to those without (17.5±10.2 vs. 7.2±4.1 mmolmUL-2, P=0.013). Within the 
NAFLD cohort, adipo-IR was associated with BMI (r=0.70, P<0.001), visceral adipose tissue 
(r=0.53, P=0.02), M-value (r=-0.50, P=0.003), but not with hepatic steatosis (r=0.23, 
P=0.35).  
 
Table 2. Metabolic parameters during basal, insulin-stimulated and exercise conditions in NAFLD vs. 
control  
 Control  (n=15) NAFLD (n=20) P-value 
Insulin resistance and substrate oxidation rates  
M-value (mgkgFFM-1min-1) 9.1  2.2 4.1  1.5 < 0.001 
M/I (mgkgFFM-1min-1)(mUL-1)-1 17.1  5.1  5.9  3.6 <0.001 
Adipo-IR (mmolmUL-2) 2.2  1.3  11.1  8.6 0.001 
Basal Fatox (mgkgFFM-1min-1) 1.5  0.4 1.2  0.3 0.024 
Basal CHOox (mgkgFFM-1min-1) 1.6  0.8  2.4  0.7 0.004 
Insulin-stimulated Fatox (mgkgFFM-1min-1) 0.8  0.3 1.0  0.3 0.17 
Insulin-stimulated CHOox (mgkgFFM-1min-1) 3.6  0.7  3.0  0.7 0.036 
Maximal fat oxidation and aerobic fitness  

VO2 peak (mlkg-1min-1) 
43.8  9.6 21.0    6.0 < 0.001 

VO2 peak (mlkgFFM-1min-1) 52.7  19.0 33.6  6.7 < 0.001 
  
Workload at 
VO2 peak  (W) 285  72 155   68 < 0.001 
MFO (mgkgFFM-1min-1) 5.8  3.7 2.5  1.4 0.002 
Workload at MFO (W) 103.4  47.3  45.7  17 < 0.001 
Fatmax (%
VO2 peak ) 48.9  11.2 50.2  15.9 0.80 
M-value, glucose infusion rate in the steady-state of the hyperinsulinemic-euglycemic clamp; M/I, 
insulin sensitivity index; Adipo-IR, adipose tissue insulin resistance index; Fatox, fat oxidation rates, 
CHOox, carbohydrate oxidation rates, 
VO2 peak , peak oxygen uptake; MFO, maximal fat oxidation; W, 
Watts; Fatmax, exercise intensity eliciting maximal fat oxidation.  
 
Substrate oxidation under basal conditions  
After adjusting for FFM, total energy expenditure in the basal state was not different between 
groups (P=0.26). However, the proportion of energy derived from fat and CHO did differ 
between groups, with NAFLD patients oxidizing more CHO (2.410.73 vs. 1.60.77 
mgkgFFM-1min-1, P=0.004) and less fat (1.220.28 vs. 1.490.39 mgkgFFM-1 min-1, 
P=0.024) than controls (Figure 1A and 1B). This was confirmed by the higher RQ in patients 
with NAFLD (0.820.04 vs. 0.780.03, P=0.007, Figure 1C).  
Within the overweight/obese NAFLD group, basal RQ was positively correlated with hepatic 
steatosis (r=0.57, P=0.01, Figure 2A). This association was confirmed by linear regression 
multivariate analysis, after controlling for BMI, % body fat, visceral adipose tissue, 
subcutaneous adipose tissue, age and gender (standardized β=0.56, P=0.021). Indeed, basal 
RQ was not correlated to visceral adipose tissue (r=0.07, P=0.77), % body fat (r=0.31, 
P=0.19) and BMI (r=0.29, P=0.23, Figure 2B), and was not significantly different in patients 
with NAFLD with BMI < or 33 kg/m2 (supplementary material). Further, basal RQ was 
significantly lower in the 6 patients with a NAS of <5 compared to the 14 patients with 
NAS5 (0.790.02 vs. 0.830.03, P=0.008, Figure 2C), and this difference also persisted after 
adjusting for visceral adipose tissue (P=0.01), % body fat (P=0.01) and BMI (P=0.02). 
  
Patients with NAFLD showed evidence of reduced hepatic ketogenesis with lower basal 
plasma concentrations of β-hydroxybutyrate than lean controls (0.090.03 vs 0.140.07 
mmol/L, P=0.004, Figure 3A). Within the NAFLD cohort, fasting concentrations of β-
hydroxybutyrate were inversely correlated with fasting plasma TG (r=-0.64, P=0.002, Figure 
3B) and very low-density lipoprotein (r=-0.67, P=0.002), but not correlated with fasting 
insulin (P=0.42), fasting FFA (P=0.42), % hepatic steatosis (P=0.96) or basal RQ (P=0.40). 
β-hydroxybutyrate concentrations were not different between patients with NAS <5 and those 
with NAS 5 (0.10±0.04 vs. 0.09±0.2, P=0.60), nor between patients with BMI <33 kg/m2 
and those with BMI 33 kg/m2 (supplementary material). When combining NAFLD and 
control groups, fasting concentrations of β-hydroxybutyrate were also inversely correlated 
with fasting plasma TG (r=-0.64, P<0.001) and very low-density lipoprotein (r=-0.63, 
P<0.001).  
Substrate oxidation under insulin-stimulated conditions  
Under insulin-stimulated conditions there was no apparent difference between groups in total 
energy expenditure (P=0.27). However, patients with NAFLD had lower CHOox (P=0.036, 
Figure 1C) and a lower RQ (P=0.037, Figure 1C). The switch in substrate oxidation in 
response to insulin stimulation was different between groups: NAFLD patients increased 
CHOox and suppressed Fatox to a lesser extent than controls (0.670.81 vs. 2.050.68 
mgkgFFM-1min-1, P<0.001, and -0.260.35 vs. -0.70.33 mgkgFFM-1min-1, P=0.001, 
respectively, Figure 1D). Consistently, the change in RQ from the basal state was smaller in 
NAFLD (0.040.03 vs. 0.110.04, P<0.001, Figure 1C). Hepatic steatosis was not correlated 
with change in RQ from basal to insulin-stimulated conditions (P=0.29), however there was a 
trend for the % hepatic steatosis to be correlated with the insulin sensitivity index (r=-0.40, 
P=0.09). 
  
Substrate oxidation during exercise 
Aerobic fitness, as measured by 
VO2 peak , was lower in the NAFLD group (33.66.7 vs. 
52.719.0 mlkgFFM-1min-1, P<0.001, Table 2). When cycling at the intensity eliciting 
maximal fat oxidation (Figure 4), patients with NAFLD had a lower MFO (2.541.43 vs. 
5.873.71 mgkgFFM-1min-1, P=0.002) than the control group. CHOox was not significantly 
different, but tended to be lower in NAFLD (P=0.06), while total energy expenditure 
(P<0.001) and increase in both Fatox (P=0.002) and CHOox (P=0.023) from basal to exercise 
were significantly lower in NAFLD. The intensity at which MFO was reached (Fatmax) was 
lower in NAFLD when expressed in absolute terms (45.717 vs. 103.447.3 Watts, P<0.001), 
but not in relative terms (50.215.9 vs. 48.911.2 % of VO2 peak , P=0.80). After adjusting for 

VO2 peak  by covariate analysis, MFO was not different between groups (P=0.13). MFO during 
acute exercise was not correlated with degree of steatosis (P=0.26) and was not significantly 
different in patients with NAS of <5 compared to patients with NAS5  (P=0.79). 
All the results of this study were confirmed by covariate analysis, with FFM as covariate. 
 
 
DISCUSSION 
In NAFLD, hepatic steatosis is intricately linked with a number of metabolic alterations. In 
the current study, overweight/obese patients with NAFLD demonstrated reduced whole-body 
Fatox in basal conditions and during acute exercise compared to lean controls. Within the 
overweight/obese NAFLD group, alterations in basal substrate metabolism were associated 
with more severe steatosis and more severe disease, independent of BMI and fat topography. 
  
Patients with NAFLD also had reduced basal hepatic Fatox, and this was associated with 
increased fasting circulating TG.  
The present study was designed to comprehensively investigate substrate metabolism and IR. 
It is the largest study to assess disease severity by liver histology in conjunction with whole-
body substrate metabolism and IR. Substrate oxidation was measured in three different 
physiological states: basal, insulin-stimulated and exercise, which forms an ideal cadre to 
study whole-body energy homeostasis and understand mechanisms of dysfunction. Gold 
standard techniques for the assessment of liver disease (liver histology), IR 
(hyperinsulinemic-euglycemic clamp) and body composition (dual-energy X-ray 
absorptiometry) were used. NAFLD patients with a broad spectrum of steatosis were studied 
(10-100%).  
In the patient group studied, NAFLD and obesity coexisted, therefore it was not possible to 
establish the specific contribution of each factor to the differences observed between patients 
and lean controls. For this reason, we did not limit our study to a comparison between 
NAFLD and controls, but also performed analyses within the overweight/obese NAFLD 
cohort, to establish the relationship between disease severity and substrate oxidation under 
different physiological conditions.  
In basal conditions, patients with NAFLD demonstrated an alteration in whole-body substrate 
metabolism with a lower Fatox and a higher CHOox compared to controls. The different 
outcome compared to previous studies (which showed Fatox to be lower,[11] similar,[14] or 
trending to be higher[12] in NAFLD versus controls) could be due to the heterogeneity of 
disease severity in NAFLD or to differences in plasma substrate concentrations such as 
fasting glucose and fasting FFA. Anthropometric characteristics of the study groups may also 
be implicated. Some studies have attempted to match groups for BMI by comparing lean[11] 
or moderately overweight individuals[14] with and without NAFLD. While this approach has 
  
some advantages, it also has limitations. Lean individuals with NAFLD represent only a small 
proportion of the clinical population[18, 19] and may have different genetic characteristics.[2] 
In additon, BMI is a poor indicator of body composition and body fat distribution at the 
individual level.[33]  
To determine if there was a dose effect between the severity of steatosis and basal substrate 
metabolism we performed analyses within the overweight/obese NAFLD cohort. We found 
that hepatic steatosis was positively correlated to basal RQ and that RQ was significantly 
higher in patients with more severe disease. A higher basal RQ indicates that a smaller 
proportion of whole-body total energy expenditure is derived from Fatox. These findings were 
independent of visceral adipose tissue, % body fat and BMI. These observations suggest that 
reduced whole-body Fatox in basal conditions may contribute to hepatic fat accumulation and 
may be implicated in the pathogenesis of NAFLD. Accordingly, a recent review proposed that 
alterations in fatty acid metabolism lead to an accumulation of ectopic (intrahepatic and 
intramuscular) TG, resulting in IR in liver and skeletal muscle.[6]  
In addition to lower basal rates of whole-body Fatox, the patients with NAFLD we studied had 
lower basal concentrations of -hydroxybutyrate, indicating reduced hepatic Fatox.[29] The 
lower basal -hydroxybutyrate in NAFLD despite similar basal FFA concentrations for both 
NAFLD and control suggests differential fatty acid partitioning in the liver between 
groups.[34] Indeed, very low-density lipoprotein (a product of the esterification pathway) was 
higher in NAFLD while -hydroxybutyrate (a product of the oxidative pathway) was lower. 
Basal -hydroxybutyrate was negatively correlated with very low-density lipoprotein and TG, 
both when combining groups and when performing the analysis within the NAFLD cohort. In 
animal models, an inhibition of hepatic Fatox leads to an increase in hepatic steatosis,[35, 36] 
while an increase in hepatic Fatox reduces hepatic steatosis.[37, 38] In humans, lower basal -
hydroxybutyrate concentrations were found in obese compared with lean individuals[39, 40] 
  
and in hypertriglyceridaemic compared with normolipidaemic moderately obese 
individuals.[41] Few studies have examined this issue in NAFLD, and results are inconsistent, 
with either higher[12] or similar[13, 14] -hydroxybutyrate concentrations in NAFLD vs. 
controls. In these studies the differences in hepatic Fatox between patients and controls mirror 
those for fasting FFA.[12, 13, 14]  
When studying substrate oxidation in insulin-stimulated conditions, we noted that patients 
with NAFLD increased CHOox and suppressed Fatox to a lesser extent than controls, and this 
was consistent with previous observations.[11, 12, 14] In other words, patients demonstrated 
metabolic inflexibility, which was defined by Kelley et al. as an impaired capacity to adapt 
fuel oxidation to fuel availability.[42] Assessment of IR revealed that the patients with 
NAFLD had lower M-value and lower oxidative and non-oxidative glucose disposals 
compared to the control group, indicating a global impairment in skeletal muscle glucose 
metabolism. Between-group differences in insulin sensitivity were even more apparent after 
normalizing for the insulin concentrations achieved. We acknowledge that M-value and non-
oxidative glucose disposal rate may be underestimated in this study given that the hepatic 
glucose output was not considered, however, previous research has shown that with the 
insulin dosage that was used in the present study, hepatic glucose output is minimal even in 
obese[13] or NAFLD patients.[12] Further, consistent with previous observations, we showed 
that patients with NAFLD had more severe IR in the adipose tissue than controls[12, 43] and 
that severity of adipo-IR was related to the severity of hepatic fibrosis.[44, 45]  
Another finding of the present study was that, during exercise, MFO in patients with NAFLD 
was less than half those in control participants, indicating a reduced ability to increase fat 
oxidation when performing an acute exercise session. However, the lower aerobic fitness 
appeared to contribute to the lower MFO observed in patients with NAFLD. After correcting 
for 
VO2 peak , the difference in MFO between NAFLD and control was no longer apparent. 
  
Further, the exercise intensity at which MFO occurred, Fatmax, was significantly lower in 
NAFLD compared to controls when expressed in absolute terms (W), but not when expressed 
in relative terms (%
VO2 peak ). Outcomes of studies investigating substrate oxidation during 
exercise in type 2 diabetes and obesity are divided, with some showing a lower Fatox during 
exercise in obese[46] and type 2 diabetes patients[47, 48] compared to controls, while others 
find no difference.[49, 50]  
We also observed that the aerobic fitness of patients with NAFLD was extremely low, with 
most patients falling in the lowest percentile according to the American College of Sports 
Medicine guidelines.[51] Low fitness level[52] and NAFLD[53] have been shown to be 
independently associated with the risk of cardiovascular events, however, few studies have 
assessed physical fitness quantitatively in NAFLD.  
Longitudinal studies demonstrate that lifestyle interventions aimed at increasing aerobic 
fitness improve IR,[54] and positively impact on Fatox under basal[55] and exercise[16, 56] 
conditions. A recent study showed that the magnitude of reduction in steatosis after calorie 
restriction was negatively correlated with post-treatment plasma ketone body and negatively 
correlated with post-treatment basal RQ,[57] suggesting that enhanced hepatic and whole-
body Fatox contribute to the reduction in steatosis. Therefore, approaches that enhance basal 
and exercise Fatox may have a role in the management of NAFLD. These include exercise 
training,[55] calorie restriction,[57] but also some pharmacological[58] and nutraceuticals 
agents.[59]  
In conclusion, this study showed that overweight/obese patients with NAFLD have reduced 
basal whole-body and hepatic Fatox, and reduced Fatox during exercise compared to lean 
controls. Irrespective of body composition, there was an inverse relationship between ability 
to oxidize fat in basal conditions and histological features of NAFLD. This suggests that 
reduced basal Fatox may contribute to ectopic accumulation of fat in the liver and may be 
  
implicated in the pathogenesis of NAFLD. This alteration could represent an important 
therapeutic target for new treatments in NAFLD. Behavioural and pharmacological 
approaches that promote Fatox in basal and exercise conditions warrant further investigation in 
this patient population.  
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Figures 
 
Figure 1. Fat oxidation (A) and carbohydrate oxidation (B) under basal and insulin stimulated 
conditions in 15 control vs. 20 NAFLD participants. (C) Respiratory quotient at basal and in 
the insulin-stimulated state. (D) Change in substrate utilization from basal to the insulin-
stimulated state.  P<0.05,  P<0.01 and  P<0.001 between control and NAFLD. 
Figure 2. (A) Correlation between % hepatic steatosis and basal respiratory quotient (RQ) in 
20 overweight/obese patients with NAFLD. The positive association between basal 
respiratory quotient and hepatic steatosis was maintained after controlling for BMI, % body 
fat, visceral adipose tissue, subcutaneous adipose tissue, age and gender (standardized ß=0.56, 
P=0.021). (B) Correlation between basal respiratory quotient and BMI in 20 
overweight/obese patients with NAFLD. (C) Basal respiratory quotient in patients with 
NAFLD having a NAFLD activity score (NAS) <5 (n=6) vs. patients having a score 5 
(n=14). The difference persisted after adjusting for visceral adipose tissue (P=0.01), % body 
fat (P=0.01) and BMI (P=0.02).  
  
Figure 3. (A) Fasting ß-hydroxybutyrate in 15 control vs. 20 NAFLD participants.  
P<0.01.(B) Correlation between fasting ß-hydroxybutyrate and fasting tryglicerides in 20 
overweight/obese patients with NAFLD. 
Figure 4. Fat oxidation (A) and carbohydrate oxidation (B) during exercise in 15 control vs. 
20 NAFLD participants.  P<0.01 between control and NAFLD. 
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